Skip to content

iTeos Therapeutics, Inc.

Delisted

CIK 1808865fmd_133G693QGS580604FVWCPVBBGBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2019 to Jun 30, 2025, 26 periods

Latest annual · FY2024

Millions
Total revenues
35
Operating income
(160)
Net income
(134)
Free cash flow
(100)

Latest quarter · Q2 FY2025

Millions
Total revenues
0
Operating income
(84)
Net income
(79)
Free cash flow
(43)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2021 to FY2024
-53.4%
Revenue, 5 yearsFY2019 to FY2024
n/m
Net income, 5 yearsFY2019 to FY2024
n/m

iTeos Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2024FY2023ChangeSource
Revenue$35 million$12.6 million+177.9%10-K 2025-03-05 · proof
Operating income-$159.5 million-$151.1 million10-K 2025-03-05 · proof
Net income-$134.4 million-$112.6 million10-K 2025-03-05 · proof
Cash from operating activities-$98.2 million-$103.8 million10-K 2025-03-05 · proof
Free cash flow-$99.8 million-$106.7 million10-K 2025-03-05 · proof
Total assets$687 million$667.6 million+2.9%10-K 2025-03-05 · proof
Total liabilities$96.7 million$92.4 million+4.7%10-K 2025-03-05 · proof
Cash and cash equivalents$142.1 million$251.2 million-43.4%10-K 2025-03-05 · proof
What was iTeos Therapeutics, Inc.'s revenue in fiscal 2024?
iTeos Therapeutics, Inc. reported revenue of $35 million for fiscal 2024 (the year ended Dec 31, 2024), against $12.6 million the year before (+177.9%). Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What was iTeos Therapeutics, Inc.'s operating income in fiscal 2024?
iTeos Therapeutics, Inc. reported operating income of -$159.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$151.1 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What was iTeos Therapeutics, Inc.'s net income in fiscal 2024?
iTeos Therapeutics, Inc. reported net income of -$134.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$112.6 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What was iTeos Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
iTeos Therapeutics, Inc. reported cash from operating activities of -$98.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$103.8 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What was iTeos Therapeutics, Inc.'s free cash flow in fiscal 2024?
iTeos Therapeutics, Inc. reported free cash flow of -$99.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$106.7 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What are iTeos Therapeutics, Inc.'s total assets?
As of Dec 31, 2024, iTeos Therapeutics, Inc. reported total assets of $687 million, against $667.6 million a year earlier (+2.9%). Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What are iTeos Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2024, iTeos Therapeutics, Inc. reported total liabilities of $96.7 million, against $92.4 million a year earlier (+4.7%). Source: the 10-K filed with the SEC on Mar 5, 2025. SEC
What are iTeos Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2024, iTeos Therapeutics, Inc. reported cash and cash equivalents of $142.1 million, against $251.2 million a year earlier (-43.4%). Source: the 10-K filed with the SEC on Mar 5, 2025. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1808865&period_type=annual&limit=5"

Information only, not investment advice.